AKOYA BIOSCIENCES INC. - COMMON STOCK

Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025

24 Apr 2025 07:00:01 By Nasdaq GlobeNewswire

Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas

24 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore

23 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities

02 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

17 Mar 2025 15:00:00 By Nasdaq GlobeNewswire

Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels

05 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

10 Dec 2024 07:15:38 By Nasdaq GlobeNewswire

Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone

09 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Akoya Biosciences Reports Third Quarter 2024 Financial Results

14 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel

05 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024

28 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy

07 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors

03 Oct 2024 15:00:00 By Nasdaq GlobeNewswire

Akoya Biosciences Reports Second Quarter 2024 Financial Results

05 Aug 2024 15:00:00 By Nasdaq GlobeNewswire

Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences

15 Jul 2024 15:00:00 By Nasdaq GlobeNewswire

Akoya Biosciences Reports First Quarter 2024 Financial Results

13 May 2024 15:00:00 By Nasdaq GlobeNewswire

Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows

02 May 2024 07:00:00 By Nasdaq GlobeNewswire

Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024

22 Apr 2024 15:05:00 By Nasdaq GlobeNewswire